# Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

> **NCT03275558** · PHASE1 · WITHDRAWN · sponsor: **Center Trials & Treatment**

## Conditions studied

- Recurrent Glioblastoma
- Gliosarcoma
- Anaplastic Gliomas

## Interventions

- **DRUG:** Axitinib 1 MG
- **DRUG:** Sunitinib 5 MG
- **DRUG:** Pazopanib 5 MG

## Key facts

- **NCT ID:** NCT03275558
- **Lead sponsor:** Center Trials & Treatment
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-07-17
- **Primary completion:** 2018-07-17
- **Final completion:** 2018-07-17
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision)
- **Last updated:** 2018-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03275558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03275558, "Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03275558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*